Current Therapy of Chronic Viral Hepatitis B, C and D

Schlaak, Joerg F.

doi:10.3390/jpm13060964

Cited by 4 publications

(2 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis B and C viruses have been shown to cause acute and chronic infections that lead to the development of hepatocellular carcinoma, which accounts for 90% of all liver cancer [28,29]. In our study, male CP patients without hepatitis B or C were found to have a higher risk of liver cancer.…”

Section: Discussionmentioning

confidence: 46%

The Impact of Chronic Pancreatitis on the Occurrences of Human Cancers: Real-World Data

Hsieh

et al. 2023

JCM

View full text Add to dashboard Cite

Chronic pancreatitis (CP) may induce systemic inflammation, potentially increasing cancer susceptibility. However, the link between CP and extra-pancreatic cancer remains underexplored. Employing Taiwanese National Health Insurance Database data from 2000 to 2017, we compared 5394 CP patients with 21,576 non-CP individuals through propensity score matching. CP patients exhibited a significantly higher cancer risk (adjusted hazard ratio (aHR) of 1.32 for females and 1.68 for males) and cumulative incidence (p < 0.001) compared to non-CP individuals. CP showed notable associations with pancreatic (aHR = 3.51), liver (aHR = 1.62), stomach (aHR = 2.01), and other cancers (aHR = 2.09). In terms of liver cancer, CP was significantly associated with patients without viral hepatitis, regardless of gender (aHR = 2.01 for women; aHR = 1.54 for men). No significant cancer occurrences were observed within the first year following CP diagnosis. Pancreatic or liver cancer developed in approximately half of CP patients within 2–3 years, while gastric cancer in male CP patients predominantly occurred around the fifth year after diagnosis. These findings inform potential cancer-screening plans for CP patients.

show abstract

Section: Discussionmentioning

confidence: 46%

The Impact of Chronic Pancreatitis on the Occurrences of Human Cancers: Real-World Data

Hsieh

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In this Special Issue, Schlaak gives an overview of the current treatments and developments, stating that (i) the introduction of direct-acting antivirals for treating HCV has been a boon by all accounts (at least, one might add, for those patients living in countries where these drugs are available); (ii) nowadays, HBV is generally well controllable, although a "functional cure" has not yet been achieved, which calls for novel therapeutic strategies that are currently being developed; and (iii) HDV remains the most challenging type of chronic viral hepatitis, for which therapeutic approaches with better response rates must be conceived [25].…”

Section: Chronic Viral Hepatitidesmentioning

confidence: 99%

Liver Diseases: Science, Fiction and the Foreseeable Future

Gieseler,

Baars,

Özçürümez

et al. 2024

JPM

View full text Add to dashboard Cite

This Editorial precedes the Special Issue entitled “Novel Challenges and Therapeutic Options for Liver Diseases”. Following a historical outline of the roots of hepatology, we provide a brief insight into our colleagues’ contributions in this issue on the current developments in this discipline related to the prevention of liver diseases, the metabolic dysfunction-associated steatotic liver disease (or non-alcoholic fatty liver disease, respectively), liver cirrhosis, chronic viral hepatitides, acute-on-chronic liver failure, liver transplantation, the liver–microbiome axis and microbiome transplantation, and telemedicine. We further add some topics not covered by the contributions herein that will likely impact future hepatology. Clinically, these comprise the predictive potential of organokine crosstalk and treatment options for liver fibrosis. With regard to promising developments in basic research, some current findings on the genetic basis of metabolism-associated chronic liver diseases, chronobiology, metabolic zonation of the liver, aspects of the aging liver against the background of demography, and liver regeneration will be presented. We expect machine learning to thrive as an overarching topic throughout hepatology. The largest study to date on the early detection of liver damage—which has been kicked off on 1 March 2024—is highlighted, too.

show abstract

Advances in the treatment of hepatogenous diabetes: A review

Deng,

Li,

et al. 2023

Medicine

View full text Add to dashboard Cite

Hepatogenous diabetes (HD) is a glycogen metabolism disorder that arises as a consequence of chronic liver disease. The condition is frequently detected in patients diagnosed with cirrhosis, which is a result of advanced liver disease. The prognosis for patients with HD is generally poor, and they are at a heightened risk for serious complications such as gastrointestinal bleeding, primary peritonitis, and hepatic encephalopathy. Hepatogenous diabetes progression is often associated with cirrhosis progression, which leads to the development of liver cancer and increased patient mortality. Despite the prevalence and severity of HD, no systematic treatment strategy for clinical management of the condition has been proposed by any research or institutions to date. This paper conducts an extensive review of recent advancements in HD treatment in the quest for an effective treatment approach that may improve the overall prognosis of HD.

show abstract

Current Therapy of Chronic Viral Hepatitis B, C and D

Cited by 4 publications

References 96 publications

The Impact of Chronic Pancreatitis on the Occurrences of Human Cancers: Real-World Data

The Impact of Chronic Pancreatitis on the Occurrences of Human Cancers: Real-World Data

Liver Diseases: Science, Fiction and the Foreseeable Future

Advances in the treatment of hepatogenous diabetes: A review

Contact Info

Product

Resources

About